226 related articles for article (PubMed ID: 14657087)
1. Study of the toxicity of a new lipid complex formulation of amphotericin B.
Larabi M; Pages N; Pons F; Appel M; Gulik A; Schlatter J; Bouvet S; Barratt G
J Antimicrob Chemother; 2004 Jan; 53(1):81-8. PubMed ID: 14657087
[TBL] [Abstract][Full Text] [Related]
2. Safety evaluation of ABELCET, an amphotericin B lipid complex (ABLC): toxicity studies in rats.
Zhang Z; Diener RM; Lipman JM
Int J Toxicol; 2006; 25(4):285-94. PubMed ID: 16815817
[TBL] [Abstract][Full Text] [Related]
3. Low nephrotoxicity of an effective amphotericin B formulation with cationic bilayer fragments.
Lincopan N; Mamizuka EM; Carmona-Ribeiro AM
J Antimicrob Chemother; 2005 May; 55(5):727-34. PubMed ID: 15761070
[TBL] [Abstract][Full Text] [Related]
4. Comparative immunotoxicity evaluation of amphotericin B and ABELCET, an amphotericin B lipid complex (ABLC).
Zhang Z; Lipman JM; Diener RM; Thomas P
Int J Toxicol; 2006; 25(6):487-92. PubMed ID: 17132607
[TBL] [Abstract][Full Text] [Related]
5. Effect of aggregation state on the toxicity of different amphotericin B preparations.
Espada R; Valdespina S; Alfonso C; Rivas G; Ballesteros MP; Torrado JJ
Int J Pharm; 2008 Sep; 361(1-2):64-9. PubMed ID: 18599228
[TBL] [Abstract][Full Text] [Related]
6. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ
J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of alternative dosing regimens of poly-aggregated amphotericin B.
Espada R; Valdespina S; Molero G; Dea MA; Ballesteros MP; Torrado JJ
Int J Antimicrob Agents; 2008 Jul; 32(1):55-61. PubMed ID: 18534826
[TBL] [Abstract][Full Text] [Related]
8. Decrease in Fungizone toxicity induced by the use of Lipofundin as a dilutent: an in vitro study.
de Araújo IB; Damasceno BP; de Medeiros TM; Soares LA; do Egito ES
Curr Drug Deliv; 2005 Apr; 2(2):199-205. PubMed ID: 16305421
[TBL] [Abstract][Full Text] [Related]
9. The novel lipid delivery system of amphotericin B: drug profile and relevance to clinical practice.
Rust DM; Jameson G
Oncol Nurs Forum; 1998; 25(1):35-48. PubMed ID: 9460772
[TBL] [Abstract][Full Text] [Related]
10. Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis.
Sivak O; Bartlett K; Risovic V; Choo E; Marra F; Batty DS; Wasan KM
J Pharm Sci; 2004 Jun; 93(6):1382-9. PubMed ID: 15124198
[TBL] [Abstract][Full Text] [Related]
11. Toxicity of an effective amphotericin B formulation at high cationic lipid to drug molar ratio.
Lincopan N; Borelli P; Fock R; Mamizuka EM; Carmona-Ribeiro AM
Exp Toxicol Pathol; 2006 Nov; 58(2-3):175-83. PubMed ID: 16982179
[TBL] [Abstract][Full Text] [Related]
12. Amphotericin B interactions with a DOPC monolayer. Electrochemical investigations.
Stoodley R; Shepherd J; Wasan KM; Bizzotto D
Biochim Biophys Acta; 2002 Aug; 1564(1):289-97. PubMed ID: 12101024
[TBL] [Abstract][Full Text] [Related]
13. Polyene antibiotics: relative degrees of in vitro cytotoxicity and potential effects on tubule phospholipid and ceramide content.
Zager RA
Am J Kidney Dis; 2000 Aug; 36(2):238-49. PubMed ID: 10922301
[TBL] [Abstract][Full Text] [Related]
14. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
Khan MA; Owais M
J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
[TBL] [Abstract][Full Text] [Related]
15. Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model.
Cannon JP; Fiscella R; Pattharachayakul S; Garey KW; De Alba F; Piscitelli S; Edward DP; Danziger LH
Invest Ophthalmol Vis Sci; 2003 May; 44(5):2112-7. PubMed ID: 12714650
[TBL] [Abstract][Full Text] [Related]
16. Comparative pharmacokinetics and safety of a novel lyophilized amphotericin B lecithin-based oil-water microemulsion and amphotericin B deoxycholate in animal models.
Brime B; Frutos P; Bringas P; Nieto A; Ballesteros MP; Frutos G
J Antimicrob Chemother; 2003 Jul; 52(1):103-9. PubMed ID: 12805269
[TBL] [Abstract][Full Text] [Related]
17. Side-effects of amphotericin B lipid complex (Abelcet) in the Scandinavian population.
Furebring M; Oberg G; Sjölin J
Bone Marrow Transplant; 2000 Feb; 25(3):341-3. PubMed ID: 10673711
[No Abstract] [Full Text] [Related]
18. Amphotericin B-induced nephrotoxicity: characterization of blood and urinary biochemistry and renal morphology in mice.
Tonomura Y; Yamamoto E; Kondo C; Itoh A; Tsuchiya N; Uehara T; Baba T
Hum Exp Toxicol; 2009 May; 28(5):293-300. PubMed ID: 19661263
[TBL] [Abstract][Full Text] [Related]
19. Amphotericin B in poly(lactic-co-glycolic acid) (PLGA) and dimercaptosuccinic acid (DMSA) nanoparticles against paracoccidioidomycosis.
Amaral AC; Bocca AL; Ribeiro AM; Nunes J; Peixoto DL; Simioni AR; Primo FL; Lacava ZG; Bentes R; Titze-de-Almeida R; Tedesco AC; Morais PC; Felipe MS
J Antimicrob Chemother; 2009 Mar; 63(3):526-33. PubMed ID: 19151037
[TBL] [Abstract][Full Text] [Related]
20. In-vitro and in-vivo evaluation of a new amphotericin B emulsion-based delivery system.
Tabosa Do Egito ES; Appel M; Fessi H; Barratt G; Puisieux F; Devissaguet JP
J Antimicrob Chemother; 1996 Sep; 38(3):485-97. PubMed ID: 8889723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
